3.22.2.2 html 218 271 1 false 42 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited- Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited- Consolidated Statements of Operations and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited- Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited- Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Basis of Presentation Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation- Note 2 - Basis of Presentation Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Business Combinations Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations Note 3 - Business Combinations Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Inventories Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories Note 5 - Inventories Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Intangible Assets Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets- Note 6 - Intangible Assets Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Goodwill Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill Note 7 - Goodwill Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Leases Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases Note 8 - Leases Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities Note 9 - Accrued Expenses and Other Liabilities Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Commitments and Contingencies Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies Note 10 - Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Revenue and Geographic Information Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information Note 11 - Revenue and Geographic Information Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Equity Incentive Plan Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan Note 12 - Equity Incentive Plan Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Income Taxes Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes Note 13 - Income Taxes Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Earnings Per Share ("EPS") Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps Note 14 - Earnings Per Share ("EPS") Notes 20 false false R21.htm 020 - Disclosure - Note 3 - Business Combinations (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables Note 3 - Business Combinations (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations 21 false false R22.htm 021 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements 22 false false R23.htm 022 - Disclosure - Note 5 - Inventories (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables Note 5 - Inventories (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories 23 false false R24.htm 023 - Disclosure - Note 6 - Intangible Assets (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables Note 6 - Intangible Assets (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets- 24 false false R25.htm 024 - Disclosure - Note 7 - Goodwill (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables Note 7 - Goodwill (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill 25 false false R26.htm 025 - Disclosure - Note 8 - Leases (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables Note 8 - Leases (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases 26 false false R27.htm 026 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables Note 9 - Accrued Expenses and Other Liabilities (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities 27 false false R28.htm 027 - Disclosure - Note 11 - Revenue and Geographic Information (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables Note 11 - Revenue and Geographic Information (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information 28 false false R29.htm 028 - Disclosure - Note 12 - Equity Incentive Plan (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables Note 12 - Equity Incentive Plan (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan 29 false false R30.htm 029 - Disclosure - Note 14 - Earnings Per Share ("EPS") (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables Note 14 - Earnings Per Share ("EPS") (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps 30 false false R31.htm 030 - Disclosure - Note 3 - Business Combinations (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual Note 3 - Business Combinations (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables 31 false false R32.htm 031 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details Note 3 - Business Combinations - Consideration Transferred (Details) Details 32 false false R33.htm 032 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) Details 33 false false R34.htm 033 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details Note 3 - Business Combinations - Intangible Assets Acquired (Details) Details 34 false false R35.htm 034 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Details 35 false false R36.htm 035 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details Note 4 - Fair Value Measurements - Contingent Consideration (Details) Details 36 false false R37.htm 036 - Disclosure - Note 5 - Inventories (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual Note 5 - Inventories (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables 37 false false R38.htm 037 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details Note 5 - Inventories - Summary of Inventories (Details) Details 38 false false R39.htm 038 - Disclosure - Note 6 - Intangible Assets (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual Note 6 - Intangible Assets (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables 39 false false R40.htm 039 - Disclosure - Note 6 - Intangible Assets - Summary of Intangible Assets (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details Note 6 - Intangible Assets - Summary of Intangible Assets (Details) Details 40 false false R41.htm 040 - Disclosure - Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Details 41 false false R42.htm 041 - Disclosure - Note 8 - Leases (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual Note 8 - Leases (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables 42 false false R43.htm 042 - Disclosure - Note 8 - Leases - Future Minimum Rental Payments for Leases (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details Note 8 - Leases - Future Minimum Rental Payments for Leases (Details) Details 43 false false R44.htm 043 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) Details 44 false false R45.htm 044 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual Note 10 - Commitments and Contingencies (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies 45 false false R46.htm 045 - Disclosure - Note 11 - Revenue and Geographic Information (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual Note 11 - Revenue and Geographic Information (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables 46 false false R47.htm 046 - Disclosure - Note 11 - Revenue and Geographic Information - Revenues (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details Note 11 - Revenue and Geographic Information - Revenues (Details) Details http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables 47 false false R48.htm 047 - Disclosure - Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) Details 48 false false R49.htm 048 - Disclosure - Note 12 - Equity Incentive Plan (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual Note 12 - Equity Incentive Plan (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables 49 false false R50.htm 049 - Disclosure - Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Details 50 false false R51.htm 050 - Disclosure - Note 12 - Equity Incentive Plan - Stock Options (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details Note 12 - Equity Incentive Plan - Stock Options (Details) Details 51 false false R52.htm 051 - Disclosure - Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Details 52 false false R53.htm 052 - Disclosure - Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) Details 53 false false R54.htm 053 - Disclosure - Note 12 - Equity Incentive Plan - Performance Stock Units (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details Note 12 - Equity Incentive Plan - Performance Stock Units (Details) Details 54 false false R55.htm 054 - Disclosure - Note 13 - Income Taxes (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual Note 13 - Income Taxes (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes 55 false false R56.htm 055 - Disclosure - Note 14 - Earnings Per Share ("EPS") (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual Note 14 - Earnings Per Share ("EPS") (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables 56 false false R57.htm 056 - Disclosure - Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Details http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables 57 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 32 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DeferredTaxAssetsValuationAllowance, us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProductWarrantyAccrual, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod - anik20220930_10q.htm 8, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 anik20220930_10q.htm anik-20220930.xsd anik-20220930_cal.xml anik-20220930_def.xml anik-20220930_lab.xml anik-20220930_pre.xml ex_440237.htm ex_440238.htm ex_440239.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true